N-acetyl cysteine in schizophrenia: A double blind randomised placebo controlled trial

INTERVENTION: This is a six month study with a four to six week post‐disconinuation visit. The trial involves taking 2g of n‐acetyl cysteine per day in addition to the participant's usual treatment. CONDITION: Schizophrenia PRIMARY OUTCOME: Assessment of involuntary movements CGI Cognitive testing GAF PANSS SOFAS SECONDARY OUTCOME: Safety data such as blood pressure, BMI, and routine blood testing. INCLUSION CRITERIA: DSM‐IV diagnosis of schizophrenia, have a PANSS score of >55 or at least two items in the positive and/or negative items being >3 AND/OR have a CGI‐S >3, be utilising effective contraception if of child‐bearing age.